Where Megatrends
Meet Medicine

Thematic investing begins with a question: which structural forces are powerful enough, durable enough, and broad enough that they will drive demand for specific goods and services for decades — regardless of which political party is in power, which country is growing fastest, or what the Federal Reserve does next? These forces are called megatrends, and the best investment opportunities sit at the intersection of several of them at once.

Stryker Corporation (NYSE: SYK) is one of the clearest examples of a company positioned at exactly that intersection. It is a global medical-technology business whose core products — robotic joint-replacement systems, surgical instruments, neurosurgery tools, emergency medical equipment, and hospital beds — are demanded more heavily as the world grows older, wealthier, more urban, and more technologically sophisticated. The five megatrends examined below each independently support growing demand for Stryker's products. Together, they make a structural case that is difficult to dismiss.

This is not simply a thesis statement. Stryker's actual financial results — sourced directly from its SEC filings — show that organic revenue has grown at double-digit rates for multiple consecutive years. The business is not waiting for megatrends to arrive. It is already harvesting them.

A Personal Note — and an Expensive Lesson in Incomplete Analysis

My relationship with Stryker started in 2003. I was in my third year of an undergraduate degree in finance — specifically enrolled in 72-371, Intermediate Finance. The course included a project that has stayed with me ever since: research a publicly traded company, apply both technical and fundamental analysis, and arrive at a fair value for the stock.

I chose Stryker. I remember wrestling to finish the assignment on time — the kind of deadline pressure that makes you reach for the fastest available tools rather than the most rigorous ones. What I reached for, heavily, were charts. Technicals. I looked at price patterns, moving averages, support and resistance levels. The fundamental analysis I applied was thin by comparison — some basic ratio work, a rough valuation. When I assembled everything, my conclusion was that Stryker was worth approximately $45 per share — and that at where it was trading, it was overvalued and not worth buying.

An overvalued stock, I reasoned, was a stock to avoid. I had talked myself out of it. I moved on.

I think about that assignment often. The actual closing market price of Stryker at year-end 2003 was $85.01 per share (pre-2004 split), which is $42.51 on a post-split equivalent basis. My $45 estimate was barely above that — close enough that a more confident analyst might even have called it cheap. Instead I read it as fully priced, decided it had nothing to offer, and passed. And then the stock proceeded to compound for two decades. The market was not wrong. My model was just standing still — frozen on a single number while the business underneath it kept moving.

The story has a sting in the tail that is worth being honest about. Using the actual year-end 2003 market price of $42.51 (post-split equivalent) as the entry point, Stryker's price appreciation over 23 years delivers an 8.6% CAGR — below the S&P 500's estimated total return of ~10.3% over the same period. With dividends reinvested, the total return rises to an estimated 9.8% CAGR — still slightly below the index. On the numbers, the market was not obviously wrong to price Stryker where it did in 2003 — and neither, it turns out, was my $45 estimate badly off. A well-run business priced about right and delivering close-to-index compounding is exactly what a quality screen is supposed to find — not a hidden 10-bagger, but a durable, lower-volatility compounder that earns its keep over decades.

The real cost of the assignment was not missing a 10-bagger. It was the habit of thinking it encouraged: that a stock trading near your estimated fair value is overvalued, finished, nothing left to offer. Static fair value analysis — the kind you get from a DCF using conservative assumptions and no structural growth thesis — hands you a single number and tempts you to treat it as a verdict. It systematically blinds you to businesses whose growth runway is long, whose competitive position strengthens over time, and whose demand is driven by forces that compound alongside demographics. In 2003, the US population aged 65 and over was roughly 35 million. By 2026, that number is approaching 60 million. That is not a surprise. That was always in the data. It just required macro-trend thinking to see it — and I had let a static price target talk me out of looking.

Had I leaned harder on fundamental analysis — free cash flow margins, reinvestment rate, competitive moat — and incorporated the demographic and technological tailwinds that were already clearly in motion, I would likely have arrived at a materially higher fair value. Not because the assumptions would have been aggressive, but because they would have been honest about what the business was actually capable of.

The Demographic Case — Demand That Cannot Be Disrupted

The most powerful argument for Stryker is the simplest: joints wear out. The human hip and knee are not designed for 80 years of use under modern conditions — sedentary work followed by recreational sport, combined with rising rates of obesity and increasing life expectancy. Osteoarthritis affects an estimated 500 million people globally. The number of total hip and knee replacements performed annually is growing at roughly 3–5% per year globally in volume terms, and demand for these procedures is not sensitive to economic cycles in the way that, say, demand for a new car or a holiday is. Pain and immobility are not discretionary inconveniences. They are medical necessities, and increasingly, they are treated as such by patients and healthcare systems alike.

What makes this demographic argument structural rather than simply temporal is the age profile of the global population. The baby boom cohort — the largest generation in history — is now entering its 70s and 80s, precisely the age range in which joint-replacement procedures peak. This wave is not a forecast. It is already in the population data. It will take 20 years to work through fully. Any company with a leadership position in joint replacement technology is positioned to harvest this demand for a generation.

The Mako Moat — Technology Working For Stryker, Not Against It

One of the most common risks cited for medical-device companies is technological disruption — the fear that robotic surgery, AI diagnostics, or some other innovation will render their products obsolete. For Stryker, this risk is largely inverted. Stryker is the disrupting technology. Its Mako robotic surgical platform is one of the most widely adopted surgical robots in orthopaedics, and its installed base creates a compounding economic advantage that is structural, not temporary.

The economics work as follows: Stryker sells or places a Mako system in a hospital. The capital cost is significant — typically $1–2 million USD per unit — which creates an immediate switching cost. The hospital then trains its surgeons on Mako, builds its scheduling and credentialing processes around the platform, and begins performing procedures. From that point, the hospital sources its implants, cutting accessories, and disposables from Stryker — because only Stryker implants are designed and cleared to work with the Mako system. The installed base becomes a recurring-revenue engine. And critically, the clinical outcomes data from Mako procedures — better implant alignment, reduced readmission rates, faster recovery — continues to strengthen the evidence base that drives further hospital adoption.

Screen Compatibility and the Halal Lens

Stryker passes every exclusion screen cleanly. It has no involvement in gambling, alcohol, or weapons. It is not a bank and has no lending business. It earns no material financing or interest revenue. It operates in medical technology — an unambiguously permissible sector under halal investment principles.

The secondary screening step — checking interest income as a proportion of total revenue and leverage against the standard halal debt threshold — should be verified against your specific framework (DJIM or AAOIFI criteria are the most widely used). As with all holdings in this portfolio, incidental interest on corporate cash is expected and does not in itself trigger exclusion; what matters is the ratio. Given Stryker's scale and cash-generative model, this is unlikely to be a concern, but the verification step is the investor's responsibility.

From a Fama-French factor perspective, Stryker would be expected to load positively on RMW (profitability) — consistent with the portfolio's overall tilt — and roughly neutral on HML given its growth-at-reasonable-price valuation. Its market beta has historically been sub-1, reflecting the defensive characteristics of healthcare demand. It belongs alongside Abbott in the portfolio as a healthcare name with genuine structural growth, rather than as a defensive staple with flat cash flows.

Why It Is Not Yet in the Current Portfolio — and Why It Should Be Considered

The 20-name portfolio presented in the main research was constructed before this analysis was completed. Abbott (ABT) occupies the healthcare slot, and the data from the factor regression shows Abbott's CFO CAGR at 3.9% — modest — and its alpha at –2.2% annualised. Stryker's double-digit organic revenue growth and consistent operating leverage suggest it would score more favourably on the CFO quality screen. A rebalancing analysis that substitutes some or all of the Abbott allocation toward Stryker — and checks the resulting portfolio's RMW loading and CFO CAGR — is the logical next step for this portfolio.

It is also worth noting that Stryker's Q1 2026 organic growth of 4.1% was temporarily suppressed by a cybersecurity incident — not a structural deterioration in demand. Management maintained full-year guidance, and the underlying volume trend in orthopaedics and MedSurg remained intact. A single-quarter disruption does not change the megatrend thesis; if anything, the market's reaction to such events can create entry opportunities.